ABSTRACT
The Allergan board member listened attentively to the words of a competitor to Botox-the popular drug used to treat facial wrinkles and a lot more. This was nothing to smile about. The drug had not had much competition in the USA since FDA approval on April 15, 2002; but there appeared to be competition on the horizon-enough to frown at. In 2008, Reloxin, another wrinkle remover with similar chemical composition to Botox, was rumored to be near FDA approval. Why had Botox done so well for Allergan all these years? Had it been only because of its monopoly position in the USA? Could the advantage be sustained?
